NO20073725L - CCI-779-polymorf og dens anvendelse - Google Patents

CCI-779-polymorf og dens anvendelse

Info

Publication number
NO20073725L
NO20073725L NO20073725A NO20073725A NO20073725L NO 20073725 L NO20073725 L NO 20073725L NO 20073725 A NO20073725 A NO 20073725A NO 20073725 A NO20073725 A NO 20073725A NO 20073725 L NO20073725 L NO 20073725L
Authority
NO
Norway
Prior art keywords
cci
polymorph
polymorphic form
present
provides
Prior art date
Application number
NO20073725A
Other languages
English (en)
Inventor
Subodh S Deshmukh
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20073725L publication Critical patent/NO20073725L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer CCI-779 polymorf form II. Foreliggende oppfinnelse tilveiebringer også prosesser for fremstilling av CCI-779 polymorf form II og farmasøytiske preparater omfattende CCI-779 polymorf form II. ?? ?? ?? ?? 1
NO20073725A 2005-02-09 2007-07-18 CCI-779-polymorf og dens anvendelse NO20073725L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65137405P 2005-02-09 2005-02-09
PCT/US2006/003098 WO2006086172A1 (en) 2005-02-09 2006-01-25 Cci-779 polymorph and use thereof

Publications (1)

Publication Number Publication Date
NO20073725L true NO20073725L (no) 2007-09-05

Family

ID=36570939

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073725A NO20073725L (no) 2005-02-09 2007-07-18 CCI-779-polymorf og dens anvendelse

Country Status (19)

Country Link
US (1) US7442707B2 (no)
EP (1) EP1856130A1 (no)
JP (1) JP2008530090A (no)
KR (1) KR20070107030A (no)
CN (1) CN101115759A (no)
AR (1) AR052479A1 (no)
AU (1) AU2006213061A1 (no)
BR (1) BRPI0607932A2 (no)
CA (1) CA2595766A1 (no)
CR (1) CR9257A (no)
GT (1) GT200600044A (no)
IL (1) IL184560A0 (no)
MX (1) MX2007009590A (no)
NO (1) NO20073725L (no)
PE (1) PE20060996A1 (no)
RU (1) RU2007129264A (no)
TW (1) TW200638932A (no)
WO (1) WO2006086172A1 (no)
ZA (1) ZA200706628B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
RU2008120670A (ru) * 2005-12-07 2010-01-20 Вайет (Us) Масштабируемый способ получения 42-сложного эфира рапамицина из 42-сложного эфира рапамицина бороната
RU2008120712A (ru) * 2005-12-07 2010-01-20 Вайет (Us) Способы получения кристаллического рапамицина и определения кристалличности соединений рапамицина при помощи дифференциальной сканирующей калориметрии
KR20080077618A (ko) * 2005-12-07 2008-08-25 와이어쓰 정제된 결정체 ｃｃｉ-779 의 제조 방법
TW200824713A (en) * 2006-10-18 2008-06-16 Wyeth Corp Processes for the synthesis of individual isomers of mono-PEG CCI-779
CN102282457A (zh) * 2009-01-21 2011-12-14 拜康有限公司 确定西罗莫司稳定性的方法和制备其稳定形式的工艺
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
CN109020995A (zh) * 2017-06-12 2018-12-18 鲁南制药集团股份有限公司 一种替西罗莫司的晶型物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
TWI256395B (en) 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
CA2455311A1 (en) 2001-08-22 2003-03-06 Wyeth Rapamycin dialdehydes
EP1419154B1 (en) 2001-08-22 2005-10-05 Wyeth Rapamycin 29-enols
WO2005010010A1 (en) 2003-07-16 2005-02-03 Wyeth Cci-779 isomer c
PT1658295E (pt) * 2003-08-07 2007-09-25 Wyeth Corp Síntese regiosselectiva de cci-779
AU2004270154A1 (en) * 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
EP1737869A1 (en) * 2004-04-14 2007-01-03 Wyeth a Corporation of the State of Delaware Regiospecific synthesis of rapamycin 42-ester derivatives

Also Published As

Publication number Publication date
US20060178392A1 (en) 2006-08-10
JP2008530090A (ja) 2008-08-07
WO2006086172A1 (en) 2006-08-17
GT200600044A (es) 2006-11-09
CN101115759A (zh) 2008-01-30
CA2595766A1 (en) 2006-08-17
AU2006213061A1 (en) 2006-08-17
MX2007009590A (es) 2007-09-12
KR20070107030A (ko) 2007-11-06
RU2007129264A (ru) 2009-03-20
AR052479A1 (es) 2007-03-21
US7442707B2 (en) 2008-10-28
TW200638932A (en) 2006-11-16
BRPI0607932A2 (pt) 2016-11-08
EP1856130A1 (en) 2007-11-21
CR9257A (es) 2007-11-23
IL184560A0 (en) 2007-10-31
PE20060996A1 (es) 2006-11-13
ZA200706628B (en) 2010-01-27

Similar Documents

Publication Publication Date Title
NO20071050L (no) Rapamycin-polymorf II og anvendelser derav
SE0301372D0 (sv) Novel compounds
ATE528989T1 (de) Kristalline feste rasagilin-base
MX2007005221A (es) Formas cristalinas de ascomicina y preparacion de ellas.
EP1765391A4 (en) BACTERIAL COMPOSITIONS FOR THE TREATMENT OF CANCER
EA200970156A1 (ru) Пиридизиноновые производные
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
EA200800546A1 (ru) Бензимидазолтиофеновые соединения в качестве ингибиторов polo-подобных киназ (plk)
SE0301373D0 (sv) Novel compounds
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
PL2207786T3 (pl) 2'-fluoro-2'-deoksy tetrahydrouryny jako inhibitory dezaminazy cytydyny
DK3219705T3 (da) Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
SE0101675D0 (sv) Novel composition
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
WO2009067686A8 (en) Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
IN2012DN03085A (no)
MX2012002542A (es) Compuestos y composiciones como inhibidores de cinasa de proteina.
ECSP045088A (es) Forma polimorfica de rimonabant, su procedimiento de preparacion y composiciones farmaceuticas que la contienen
DK1695710T3 (da) Krystallinsk betad-form af ivabradinhydrochlorid, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende denne
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
WO2007064553A3 (en) Thiazole derivatives as cxcr3 receptor modulators
NO20060392L (no) Kombinasjon av SRC kinase inhibitorer kemoterapeutiske midler for behandling av proliferative sykdommer
WO2007066337A3 (en) Jasmonate derivatives, pharmaceutical compositions and methods of use thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application